CapLaw-2021-56

AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, on 27 July 2021 announced that it is acquiring Affiris SA’s portfolio of therapeutics targeting alpha-synuclein (a-syn) as well as cash for 7.1 million shares based on a price of USD 8.26 per common share of AC Immune. The acquisition is subject to customary regulatory approval in Austria and expected to complete at the beginning of Q4 2021. Concurrent with the asset acquisition, AC Immune’s cash position, as well as its investor base, is also being strengthened by a total of USD 30 million in…